Nancy Wong
Registered Nurse · San Francisco, CANPI 1417246489
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $11,729 of the $14,344 with a category attached, or 81.8%. Johnson & Johnson accounts for 88.8% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2023 at $12,754 and has fallen 99.8% since, to $21 in 2025. Among registered nurse clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 30 payments — averaging $478.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$13K
- Amgen$1K
- Janssen Scientific Affairs, LLC$128
- Astellas Pharma US Inc$99
- Ipsen Biopharmaceuticals, Inc$97
- Pharmacyclics LLC, An Abbvie Company$67
- plus $95 from 3 others
What the payments were for
- Consulting fees$1,1258%
- Speaking & faculty fees$11,72982%
- Travel & lodging$4873%
- Food & beverage$9046%
- Education$991%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 19 | $12,733 |
| Amgen | 1 | $1,125 |
| Janssen Scientific Affairs, LLC | 1 | $128 |
| Astellas Pharma US Inc | 1 | $99 |
| Ipsen Biopharmaceuticals, Inc | 1 | $97 |
| Pharmacyclics LLC, An Abbvie Company | 3 | $67 |
| AbbVie | 2 | $41 |
| EMD Serono, Inc. | 1 | $31 |
| Genmab U.S., Inc. | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,344 in reported general payments places this provider in the 95th percentile of 533 registered nurse providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 14 | $12,647 |
| Atovaquone | 30 | $12,425 |
| Entecavir | 11 | $2,658 |
| Acyclovir | 95 | $1,948 |
| ValacyclovirValacyclovir Hcl | 11 | $1,129 |
| Oxycodone Hcl | 18 | $514 |
| Gabapentin | 26 | $349 |
| Potassium Chloride | 21 | $260 |
| Duloxetine Hcl | 12 | $214 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 14 | $79 |
| Lorazepam | 16 | $78 |
Paid to pharmacies, not to this prescriber.
Other registered nurse in San Francisco
- Cristina SykesSan Francisco$3K
- Anna JonesSan Francisco$2K
- Irina DariychukAntelope$242K
- Sandra DewarLos Angeles$50K
- Naomi GedionLos Angeles$22K
- Annie SongOakland$6K
- Ridhima SoftaBakersfield$6K
- Jennifer CorbettOakhurst$5K
- Candice WhealonLos Angeles$5K
- Suzanne FarrarCarlsbad$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.